medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2009, Number 1

<< Back Next >>

Arch Neurocien 2009; 14 (1)

A case report of obstinate gambling addiction - author’s own experience

Tomasz RL, Krzysztof PJ

Language: English
References: 34
Page: 69-72
PDF size: 64.08 Kb.


ABSTRACT

Some authors regard gambling as addiction. Detailed psychiatric examination revealed obsessive-compulsive syndrome in patient. The author treated the patient systematically with individual psychotherapy and sertraline from low doses up to the maximal dose (i.e. about 200 mg daily). A complete remission of the obsessive-compulsive syndrome was achieved. A number of indirect proofs demonstrate a significant role of sertraline in the aetiology of obsessive- compulsivesyndrome. The most important evidence is the effectiveness of the drugs from the group of selective inhibitors of serotonin central reuptake (SI-5HT) in the treatment of obsessive-compulsive syndrome. Sertraline is safe and effective in the treatment of obsessivecompulsive syndrome. Very numerous authors have used sertraline in the treatment of this syndrome with evidently good effect. Drug doses ranged from 50 to 200 mg daily.


REFERENCES

  1. Aguglia E, Casacchia M, Cassano GB. University of Trieste, Italy, Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. International ClinicalPsychopharmacology 1993;8(3):197-202.

  2. Bennie EH, Mullin JM, Martindale JJ. Leverndale Hospital, Glasgow, UK. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiat 1995; 56 (6): 229-37.

  3. Beshay H, Pumarega AJ. James H. Quillen College of Medicine, East Tennessee State University, Quillen/Mountain Home Veterans Administration Medical Center, Johnson City 37684, USA. Sertraline treatment of mood disorder associated with prednisone: a case report. J Child Adolescent Psychopharmac1998; 8 (3): 187-93.

  4. Biri H, Isen K, Sinik Z. Department of Urology, Medical School of Gazi University, Ankara, Turkey. Sertraline in the treatment of premature ejaculation: a double-blind placebo-controlled study. International Urol Nephrol 1998, 30 (5): 611-5.

  5. Brady KI, Sonne SC, Roberts JM. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29426, USA. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiat 1995; 56 (11): 502-5.

  6. Chouinard G. Department of Psychiatry, University of Montreal, Hospital Louis H. Lafontaine, Quebec, Canada. Sertraline in the treatment of obsessive-compulsive disorder: two doubleblind, placebo-controlled studies. Internat Clin Psychopharmacol 1992;7 Suppl. 2:37-41.

  7. Croft H, Settle E Jr., Houser T, Charleston Area Medical Center, West Virginia, USA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual funcioning of sustained-release bupropione and sertraline. Clin Therapeut 1999;21(4):643-58.

  8. Davis SM, Harrison WM, Keller MB. Rhode Island Hospital and Brown University, Providence 02903, USA. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychi 1998; 59 (11): 608-19.

  9. Ekselius L, Von Knorring L. Department of Neuroscience , Psychiatry, University Hospital, Uppsala, Sweden. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.

  10. Finkel SL, Richter EM, Clary CM. Northwestern University Medical School, Department of Psychiatry and Behavioral Sciences, Chicago, IL 60611-3317, USA. Comparative efficiency and safety of sertraline versus nortriptyline in major depression in patiens 70 and older. Internat Psychogeriatrics 11 (1): 85-99.

  11. Griest J, Chouinard B, DuBoff B, Dean Foundation for Health, Research, and Education, Madison, Wis., USA. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen sychiat 1995; 52(4):289-96.

  12. Greist JH, Jefferson JW, Kobak KA. Dean Foundation for Health, Research and Education, Madison, WJ 53/17, USA. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Internat Clinl Psychopharmacol 1995;10 (2): 57-65.

  13. Grignaschi G, Samanin R. Instituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Role of serotonin receptors in the effects of sertraline on feeding behaviour. Psychopharmacology 1993; 110(1-2):203-8.

  14. Hirschfeld RM, Russell JM, Delgado PL. Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch at Galveston 77555-0429, USA. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiat 1998; 59 (12): 669-75.

  15. Jermain DM, Preece CK, Syles RL, Department of pharmacy, Scott and White Memorial Hospital, Temple, Tex., USA. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, cross-over study. Archiv Fam Med 1999; 8 (4): 328-32.

  16. Kant R, Smith-Seemiller L, Zeiler D, Head Injury Clinic, St. Francis Medical Center, Pittsburgh, PA 15524, USA. Treatment of agression and irritability after head injury. Brain Injury 1998; 12(8):661-6.

  17. Katzelnick DJ, Kobak KA, Greist JH, Foundation for Health, Research and Education, Madison, WJ 53/17, USA. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiat 1985;152(9):1368-71.

  18. Kavoussi RJ, Coccaro EF, Department of Psychiatry, Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129. An open trial of sertraline in personality disorder in patients with impulsive aggression. J Clin Psychiat 1994;55(4):137-41.

  19. Keller MB, Gelenberg AJ, Hirschfeld RM, Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, RJ 02912, USA. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiat 1998; 59(11):598-607.

  20. Keller MB, Harrsion W, Fawcett JA, Butler Hospital, Brown. University, Providence, RI 02912, USA. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull 1995; 31 (2): 205-12.

  21. Keller MB, Kocsis JH, Thase M, Department of Psychiatry, Butler Hospital, Brown University, Providence, RJ 02906, USA. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280 (19): 1665-72.

  22. Kirli S, Caliskan M, Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophrenia Res 1998;33 (1-2).

  23. Kroning MH, Apter J, Asnis G, Department of Psychiatry, Millside Hospital of LIJMC, Glen Oaks, New York, USA. Placebocontrolled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19(2):172-6.

  24. Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Progress in Neuro-Psychopharmacol Biol Psychiat 1998;22 (5): 741-8

  25. Lauterbach EC, Department of Psychiatry and Behavioral Sciences, Mercer University School of Medicine, Macon, Georgia, USA. Catatonia - like events after valproic acid with risperidone and sertraline. Neuropsychiat Neuropsychol Behavil Neurol 1998; 11 (3): 157-63.

  26. Levin ID, Briggs SJ, Christopher NC, Department of Psychiatry, Duke University, Durham, NC 27710. Pharmacol, Bioch Behav 1993;44 (1): 51-61.

  27. Londborg PD, Wokow R, Smith WT, Summit Research Network,Seattle, Washington 98104, USA. Sertraline in the treatment of panic disorder. A multi-site,double-blind, placebo-controlled, fixed-dose investigation. Brit J Psychiat 1998;173: 54-60.

  28. Luketsos GG, Taragano F, Freisman GJ, Neuropsychiatry and Memory Group, John Hopkins University, Baltimore, MD, USA. Major depression and its response to sertraline in primary care vs Psychiatric office practice patients, results of an open-label trial in Argentina.

  29. McMahon DG, St. Luke’s Hospital Complex, Sydney, Austria. Treatment of premature ejaculation with sertraline hydrochloride. Internat J Impot Res 1998;10(3):181-4, discussion 185.

  30. Moller HJ, Gallinat J, Hegerl U, Psychiatric Hospital, Ludwig Maximilians University, Munich, Germany. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiat 1998; 31(6):170-7.

  31. Murdoch D, McTavish D, Adis International Limited, Auckland, New Zeland. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive compulsive disorder. [Review][72 refs]. Drugs 1992;44(4):604-24.

  32. Oinan TG, Department of Psychological Medicine, St.Bartholomew’s Hospital, London, United Kingdom. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Psychiat Scandinavica 1993;88(4):300-1.

  33. Pollack MH, Otto MW, Wortington JJ. Anxiety Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114-3117, USA. Arch Gen Psychiat 1998; 55(11):1010-6.

  34. Preskorn SH, Lane RM. Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Wichita 67214, USA. Sertraline 50 mg daily: the optimal dose in the treatment of depression. [Review] [55 refs]. Internat Clin Psychopharmacol 1996;10(3):129-41.




2020     |     www.medigraphic.com